Contraceptive Hormones, Immunity, and Microbiome Evaluation

CompletedOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions
Hormonal Contraception
Interventions
DRUG

Depot medroxyprogesterone acetate (DMPA)

Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks

DRUG

Etonogestrel implant (Eng-Implant)

A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.

DRUG

Levonorgestrel IUD (Lng-IUD)

The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.

Trial Locations (3)

30303

Grady Health System, Atlanta

30322

The Emory Clinic, Bldg A., 2nd Floor, 1365 Clifton Road, NE, Atlanta

30342

Atlanta Women's Center, Atlanta

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Emory University

OTHER

NCT03660046 - Contraceptive Hormones, Immunity, and Microbiome Evaluation | Biotech Hunter | Biotech Hunter